

PDF issue: 2025-12-05

# Correlation with redox potentials and inhibitory effects on Epstein-Barr virus activation of azaanthraquinones

```
Koyama, Junko ; Morita, Izumi ; Tagahara, Kiyoshi ; Osakai, Toshiyuki ; Hotta, Hiroki ; Yang, Mou Xiao ; Mukainaka, Teruo ; Nishino, Hoyoku ;…
```

### (Citation)

Chemical & Pharmaceutical Bulletin, 49(9):1214-1216

(Issue Date) 2001-09

(Resource Type)
journal article

(Version)

Version of Record

(Rights)

© 2001 Pharmaceutical Society of Japan

(URL)

https://hdl.handle.net/20.500.14094/90004300



## Correlation with Redox Potentials and Inhibitory Effects on Epstein-Barr Virus Activation of Azaanthraquinones

Junko Koyama,\*,a Izumi Morita,a Kiyoshi Tagahara,a Toshiyuki Osakai,b Hiroki Hotta,b Mou Xiao Yang, Teruo Mukainaka, Hoyoku Nishino, and Harukuni Tokuda

Kobe Pharmaceutical University,<sup>a</sup> Higashinada, Kobe 658–8558, Japan, Department of Chemistry, Faculty of Science, Kobe University,<sup>b</sup> Nada, Kobe 657–8501, Japan, and Department of Biochemistry, Kyoto Prefectural University of Medicine,<sup>c</sup> Kyoto 602–8566, Japan. Received March 26, 2001; accepted May 25, 2001

The redox potentials have been determined for nine azaanthraquinones in phosphate buffer at pH 7.2 by means of cyclic voltammetry. A definite correlation has been found between the redox potentials and the inhibitory effects of the azaanthraquinones on Epstein–Barr virus early antigen (EBV-EA) activation. It has further been shown that the correlation can be made better by introducing an electronic property, *i.e.*, the atomic charge at O<sup>11</sup> as an additional parameter.

Key words azaanthraquinone; Epstein-Barr virus activation; redox potential; cyclic voltammetry; anti-tumor promoting effect

Recently, several natural products (flavonoids, steroids, triterpenoids, quassinoids) have been studied for their inhibitory effects on 12-*O*-tetradecanoylphorbol-13-acetate (TPA)-induced Epstein–Barr virus early antigen (EBV-EA) activation and, thus, as potential anti-tumor promoting agents. <sup>1—4</sup> In a continuation of our work on the constituents of plants, we have also found inhibitory activities of anthraquinones on EBV-EA activation, and have studied their connections with electronic properties of the anthraquinones. <sup>5,6)</sup> One class of antineoplastic agents contain a planar chromophore that is inserted between two base pairs in the DNA helix, causing a local untwisting of the helix resulting in miscoding and possible cell death <sup>7)</sup>—for example, Mitoxantrone, which contains a planar anthraquinone skeleton, is a clinically useful antineoplastic agent. <sup>8)</sup>

Many anthraquinones are known to demonstrate various physiological activities, and some of their biological effects have been thought to be in intimate correlation with the redox property of the anthraquinone moiety.<sup>9)</sup> In studies of the quantitative structure-activity relationships for drugs, the redox potential is one of the most important parameters to determine the physiological activities of drugs. We employed cyclic voltammetry to determine standard redox potentials of nine anthraquinones at a physiological pH (7.2), and then found a definite correlation between the standard redox potential and the inhibitory effect (log IC<sub>50</sub>) on EBV-EA activation. 10) In this study, we report the redox potentials of nine azaanthraquinones and the structure-activity relationship between the inhibitory effects of azaanthraquinones and the redox potentials. Further, we have calculated some electronic properties of the azaanthraquinones by the PM3 method using the CAChe MOPAC program.<sup>11)</sup> It has been revealed that the atomic charge at O<sup>11</sup> may be used as another useful parameter to characterize the inhibitory effect on EBV-EA activation.

#### Experimental

Reagents and Materials Benzo[g]quinoline-5,10-dione (1) and 6-hy-droxybenzo[g]quinoline-5,10-dione (2) were synthesized from 5,8-quinolone and cyclohexadiene derivatives.

Benzo[*g*]quinoline-5,10-dione (1): IR (CHCl<sub>3</sub>) cm $^{-1}$ : 1688, 1667, 1575.  $^{1}$ H-NMR (CDCl<sub>3</sub>)  $\delta$ : 7.77 (1H, m, 3-H), 7.87 (2H, m, 6,7-H), 8.36 (2H, m, 5,6-H), 8.65 (1H, dd, *J*=8, 1.5 Hz, 4-H), 9.13 (1H, dd, *J*=4.5, 1.5 Hz, 2-H).

High resolution (HR)-MS m/z: 209.0489 (M<sup>+</sup>, Calcd for C<sub>13</sub>H<sub>7</sub>NO<sub>2</sub>: 209.0476).

6-hydroxybenzo[*g*]quinoline-5,10-dione (**2**): IR (CHCl<sub>3</sub>) cm<sup>-1</sup>: 1682, 1633, 1579. <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$ : 7.25 (1H, d, J=8 Hz, 6-H), 7.78 (1H, dd, J=8, 5 Hz 3-H), 7.83 (1H, d, J=8 Hz, 7-H), 8.03 (1H, d, J=8 Hz, 8-H), 8.68 (1H, d, J=8 Hz, 4-H), 9.16 (1H, d, J=5 Hz, 2-H), 13.02 (1H, s, OH). HR-MS m/z: 225.0441 (M<sup>+</sup>, Calcd for C<sub>13</sub>H<sub>7</sub>NO<sub>3</sub>: 225.0426).

6,9-Dihydroxy-2-methylbenzo[g]quinoline-5,10-dione (3), 3-methylbenzo[g]quinoline-5,10-dione (4), 9-hydroxy-3-methylbenzo[g]quinoline-5,10-dione (5), 6,9-dihydroxy-3-methylbenzo[g]quinoline-5,10-dione (6), 4-methylbenzo[g]quinoline-5,10-dione (7), 9-hydroxy-4-methylbenzo[g]quinoline-5,10-dione (8), and 6,9-dihydroxy-4-methylbenzo[g]quinoline-5,10-dione (9) were synthesized from naphthoquinones using the Diels-Alder reaction.<sup>5)</sup> The tissue culture reagents, TPA, *n*-butyric acid and other reagents, were from Nacalai Tesque. EBV-genome-carrying lymphoblastoid cells (Raji cells derived from Burkitt's lymphoma) were cultured in RPMI 1640 medium (Nissui), as described elsewhere.<sup>12)</sup> Spontaneous activation of EBV-EA in our subline of Raji cells was less than 0.1%.

**Procedure of EBV-EA Activation** The inhibition of EBV-EA activation was assayed using Raji cells (virus non-producer), which were cultivated in 8% fetal bovine serum (FBS) RPMI 1640 medium. The indicator cells (Raji) (1×10<sup>6</sup> ml) were incubated at 37 °C for 48 h in 1 ml of the medium containing *n*-butyric acid (4 mm, inducer) 2  $\mu$ l of TPA (20 ng/ml in dimethyl sulforide (DMSO)), and a known amount of test compound of DMSO. Smears were made from the cell suspension. The activated cells were stained by

$$\begin{array}{c|c}
 & P^5 & O \\
 & P^5 & P^2
\end{array}$$

Compd.	R1	$\aleph^2$	R <sup>3</sup>	R4	R <sup>5</sup>
1	н	н	Н	н	н
2	Н	н	Н	ОН	н
3	ÇH₃	н	н	ОН	ОН
4	н	CH <sub>3</sub>	н	н	н
5	н	$CH_3$	н	н	ОН
6	н	С <b>Н</b> 3	н	ОН	ОН
7	Н	н	CH <sub>3</sub>	н	н
8	Н	н	СНа	н	ОН
y	Н	н	CH <sub>S</sub>	ОН	ОН

Chart 1

September 2001 1215

high-titer EBV-EA positive sera from nasopharyngeal carcinoma (NPC) patients and detected by a conventional indirect immunofluorescence technique <sup>13)</sup>

In each assay, at least 500 cells were counted, and the experiments were repeated three times. The average EA induction was compared with that of positive control experiments with *n*-butyric acid (4 mm) plus TPA (32 pmol), in which EA induction was ordinarily around 40%. In this screening method, the cell viability required for the judgment of inhibitory effects was more than 60%. <sup>14)</sup>

**Electrochemical Measurements** Cyclic voltammetric measurements were performed in a similar manner as reported previously.  $^{10}$  A conventional three-electrode system was employed with a plastic-formed-carbon (PFC) working electrode (BAS, PFCE-3, surface area=0.071 cm²), a platinum counter electrode, and an Ag/AgCl (saturated KCl) reference electrode. For each voltammogram record, pretreatment of the working electrode was carried out as described previously.  $^{10}$  Test solutions were degassed with prepurified  $N_2$  gas prior to the voltammetric measurements. The electrolytic cell was water-jacketed to maintain the temperature at 25±0.1 °C.

#### **Results and Discussion**

Nine azaanthraquinones have been tested for inhibitory activities using a short-term *in vitro* assay of the EBV-EA activation induced by TPA in Raji cells. Their inhibitory effects on activation of the EA and the values of log  $IC_{50}$  are shown in Table 1.

Figure 1 shows a typical cyclic voltammogram which was recorded in the presence of 0.1 mm azaanthraquinone (1) in 0.1 м phosphate buffer (pH 7.2). The voltage scan rate was usually set on 100 mV s<sup>-1</sup>. As seen in the Figure, a well-developed, reversible wave with cathodic and anodic peaks was obtained. The cathodic peak is ascribed to the two-electron reduction of azaanthraquinone, whereas the anodic peak is due to its reoxidation. The peak separation, i.e., the difference between the cathodic and anodic peak potentials  $(\Delta E_{\rm p} = E_{\rm pa} - E_{\rm pc})$  is 28 mV, being close to the theoretical value of ca. 30 mV for a two-electron reversible wave. 15) For other azaanthraquinones, however, quasi-reversible waves with comparatively large  $\Delta E_{\rm p}$ -values (33—77 mV) were obtained (see Table 2). Even for these quasi-reversible waves, the midpoint potential  $[E_{\text{mid}} = (E_{\text{pc}} + E_{\text{pa}})/2]$  may be adequately assumed to be the apparent standard redox potential  $E^{\circ}$  under given conditions. It is generally known that the redox potentials of quinones are affected by pH. In this study, however, the values of  $E^{\circ}$  for the azaanthraquinones were determined at a physiological pH (7.2), and their connection with the anti-tumor promoting effect was examined.

In Fig. 2, the values of  $\log IC_{50}$  are plotted against  $E^{\circ}$  (in V). The plot shows that there is an apparent correlation between the values of  $\log IC_{50}$  and  $E^{\circ}$ . The  $\log IC_{50}$  has been found to be represented by a regression line:

$$\log IC_{50} = 4.308 + 3.941E^{\circ}$$

$$n = 9, \quad s = 0.189, \quad r = 0.800$$
(1)

where n, s, and r are, respectively, the number of test compounds, the standard deviation, and the correlation coefficient. Thus it has been revealed that the redox potential at pH 7.2 is an important parameter determining the EBV-EA activation of the azaanthraquinones. The more negative the  $E^{\circ}$  of the azaanthraquinones are, the stronger the anti-tumor promoting effect.

Furthermore, we examined the correlation of log IC $_{50}$  with the electronic properties of the azaanthraquinones. Table 3 shows the electronic properties, including the total energy, solvent accessible surface area, and the charges at the  $C^5$ ,

Table 1. Inhibitory Effects of Azaanthraquinones on EBV-EA Activation

% to control (% viability)					
Compound	Concentration (mol ratio/32 pmol TPA)				1 10 4)
	1000	500	500 100		log IC <sub>50</sub> <sup>a)</sup>
1	52.5	84.7	100	100	3.04
2	58.3	77.3	92.5	100	3.07
3	0 (10)	13.5 (60)	43.8 (>80)	86	2.41
4	0 (>70)	48.7 (>80)	76.5	100	2.67
5	0 (30)	15.8 (>80)	72.4	100	2.58
6	6.1 (40)	16.8 (50)	82.6 (>80)	100	2.62
7	40.6 (>70)	48.7 (>80)	77.5	100	2.82
8	0 (40)	15.4 (60)	67.4 (>80)	89.1	2.52
9	10.4 (60)	23.1 (60)	52.1 (>80)	88.6	2.52

a) The compound concentration (mol) of 50% inhibition against a positive control (100%) was defined as  $IC_{50}$ .

Table 2.  $E_{pa}$ ,  $E_{pc}$ ,  $E^{\circ}$  Values of Azaanthraquinones

	$E_{\mathrm{pa}}\left(\mathrm{V}\right)$	$E_{\rm pc}\left({ m V}\right)$	$E^{\circ a)}(V)$	$\Delta E_{\rm p}  ({\rm mV})$
1	-0.352	-0.380	-0.366	28
2	-0.304	-0.375	-0.339	71
3	-0.424	-0.468	-0.446	44
4	-0.353	-0.399	-0.376	46
5	-0.389	-0.437	-0.413	48
6	-0.449	-0.511	-0.480	62
7	-0.365	-0.402	-0.384	37
8	-0.379	-0.456	-0.418	77
9	-0.447	-0.487	-0.467	40

a) Assumed to be  $E_{\rm mid}$ 




Fig. 1. Cyclic Voltammogram of Azaanthraquinone (1) at a PFC Electrode in  $0.1\,\mathrm{M}$  Phosphate Buffer (pH 7.2)




Fig. 2. Regression Plot of  $\log$  IC<sub>50</sub> and Standard Redox Potential at pH 7.2

1216 Vol. 49, No. 9

Table 3. Electronic Properties of Azaanthraquinones

	Total energy	Solvent accessible surface area	Charge of C <sup>5</sup>	Charge of C <sup>10</sup>	Charge of O <sup>11</sup>	Charge of O <sup>12</sup>
1	-109.48	99.86	0.376	0.359	-0.266	-0.309
2	-121.72	102.48	0.410	0.354	-0.261	-0.358
3	-141.15	111.57	0.407	0.390	-0.314	-0.358
4	-116.67	106.53	0.376	0.361	-0.268	-0.310
5	-128.91	108.50	0.371	0.396	-0.317	-0.305
6	-141.15	111.52	0.405	0.392	-0.314	-0.356
7	-116.66	104.61	0.379	0.357	-0.266	-0.315
8	-121.72	102.32	0.371	0.396	-0.313	-0.299
9	-141.15	109.02	0.410	0.388	-0.312	-0.362
$r^{a)}$ (with IC <sub>50</sub> )	0.703	0.739	0.07	0.842	0.855	0.106

a) r, correlation coefficient




Fig. 3. Regression Plot of the Observed Values of log  $\rm IC_{50}$  and the Estimated Values Using Eq. 2

C<sup>10</sup>, O<sup>11</sup>, and O<sup>12</sup> atoms. Among these electronic properties, the total energy, and solvent accessible surface area show small correlations with log IC<sub>50</sub>. On the other hand, the charges at C10 and O11 demonstrate some definite correlations. Since the charges at the two atoms are compensated, respectively, the charge at O<sup>11</sup> is paid an attention to the following analysis. The oxygen atom might be the biologically active site. The charges of O<sup>11</sup> of the compounds having the hydroxyl group at the peri position of the carbonyl group adjacent to the nitrogen atom may be correlated with the enhanced inhibitory effects. As also shown in Table 3, there is no correlation of the charge at O<sup>12</sup> for log IC<sub>50</sub>. Thus, we introduced the charge at  $O^{11}$ ,  $\delta$  ( $O^{11}$ ), as an additional parameter, and performed a regression analysis. Then, it was found that log IC<sub>50</sub> can be expressed by the following equation much better than Eq. 1:

$$\log IC_{50} = 4.906 + 1.178E^{\circ} + 5.92\delta (O^{11})$$

$$n = 9, \quad s = 0.203, \quad r = 0.863$$
(2)

In Fig. 3, the observed values of  $\log IC_{50}$  are plotted against the values estimated with this Eq. 2.

In conclusion, the standard redox potentials of azaanthraquinones determined at a physiological pH (7.2) and the charge at O<sup>11</sup> are quite useful parameters for the estimation of the inhibitory effects of the azaanthraquinones on EBV-EA activation.

**Acknowledgements** This study was supported in part by Grants-in-Aid from the Ministry of Education, Science, Sports and Culture, and the Ministry of Health and Welfare, Japan.

#### References

- Konoshima T., Takasaki M., Kozuka M., Inada A., Nakanishi T., Tokuda H., Matsumoto T., Shoyakugaku Zasshi, 43, 135—141 (1989).
- Inada A., Nakanishi T., Konoshima T., Kozuka M., Tokuda H., Nishino H., Iwashima A., Shoyakugaku Zasshi, 44, 215—218 (1990).
- Diallo B., Vanhaelen M., Vanhaelen-Fastre R., Konoshima T., Kozuka M., Tokuda H., J. Nat. Prod., 52, 879—881 (1989).
- Okano M., Fukamiya N., Tagahara K., Tokuda H., Iwashima A., Nishino H., Lee K. H., Cancer Lett., 94, 139—146 (1995).
- Konoshima T., Kozuka M., Koyama J., Okatani T., Tagahara K., Tokuda H., J. Nat. Prod., 52, 987—995 (1989).
- Tagahara K., Koyama J., Ogura T., Konoshima T., Kozuka M., Tokuda H., Nishino H., Iwashima A., Chemistry Express, 7, 557—560 (1992).
- 7) Lerman L. S., J. Mol. Biol., 3, 18—30 (1961).
- Johnson R. K., Zee-Cheng R., Cancer Treatment Reports, 63, 425— 439 (1979).
- Kano K., Konse T., Nishimura N., Kubota T., Bull. Chem. Soc. Jpn., 57, 2383—2390 (1984).
- Koyama J., Tagahara K., Osakai T., Tsujino Y., Tsurumi S., Nishino H., Tokuda H., Cancer Lett., 115, 179—183 (1997).
- 11) Stewart J. J. P., J. Comp. Chem., 10, 209—220 (1989).
- 12) Ito Y., Yanase S., Fujita J., Harayama T., Takashima M., Imanaka H., Cancer Lett., 13, 29—37 (1981).
- 13) Henle G., Henle W., J. Bacteriol., 91, 1248—1256 (1966).
- Ohigashi H., Takamura H., Koshimizu K., Tokuda H., Ito Y., Cancer Lett., 30, 143—151 (1986).
- 15) Nicholson R. S., Shain I., Anal. Chem., 36, 706—723 (1964).